INDOCIN® (indomethacin) Suppositories
Patent Ductus Arteriosus (PDA) in premature infants
Approved/CommercialMarketed
Key Facts
Indication
Patent Ductus Arteriosus (PDA) in premature infants
Phase
Approved/Commercial
Status
Marketed
Company
About Assertio Holdings
Assertio Holdings is a specialty pharmaceutical company that acquires, develops, and commercializes products primarily in pain management and neurology. The company's strategy centers on leveraging its commercial infrastructure to maximize the value of its marketed products, which include INDOCIN and other established therapies. While navigating challenges such as generic competition and patent expirations, Assertio aims to grow through strategic business development and lifecycle management of its portfolio.
View full company profile